G1 Therapeutics Future Growth
Future criteria checks 5/6
G1 Therapeutics is forecast to grow earnings and revenue by 48.3% and 21.3% per annum respectively. EPS is expected to grow by 47.3% per annum. Return on equity is forecast to be 1.3% in 3 years.
Key information
48.3%
Earnings growth rate
47.3%
EPS growth rate
| Biotechs earnings growth | 24.6% |
| Revenue growth rate | 21.3% |
| Future return on equity | 1.3% |
| Analyst coverage | Low |
| Last updated | 13 Jun 2024 |
Recent future growth updates
Recent updates
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22G1 Therapeutics granted regulatory nod for cancer therapy in China
Jul 13G1 Therapeutics: Needs To Expand Labels And Commercialize Better
Apr 27Health Check: How Prudently Does G1 Therapeutics (NASDAQ:GTHX) Use Debt?
Apr 19G1 Therapeutics: Biotech With FDA Approved Drug Plus Additional Potential
Feb 08G1 Therapeutics (NASDAQ:GTHX) Has Debt But No Earnings; Should You Worry?
Dec 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 346 | 187 | 965 | 350 | 5 |
| 12/31/2025 | 95 | -21 | 24 | 0 | 5 |
| 12/31/2024 | 71 | -31 | 7 | -13 | 5 |
| 3/31/2024 | 84 | -31 | -18 | -18 | N/A |
| 12/31/2023 | 83 | -48 | -38 | -38 | N/A |
| 9/30/2023 | 78 | -71 | -56 | -56 | N/A |
| 6/30/2023 | 89 | -78 | -67 | -67 | N/A |
| 3/31/2023 | 57 | -126 | -120 | -119 | N/A |
| 12/31/2022 | 51 | -148 | -129 | -129 | N/A |
| 9/30/2022 | 47 | -154 | -133 | -133 | N/A |
| 6/30/2022 | 28 | -171 | -146 | -145 | N/A |
| 3/31/2022 | 24 | -171 | -143 | -143 | N/A |
| 12/31/2021 | 31 | -148 | -132 | -132 | N/A |
| 9/30/2021 | 42 | -134 | -129 | -129 | N/A |
| 6/30/2021 | 64 | -103 | -91 | -91 | N/A |
| 3/31/2021 | 60 | -95 | -84 | -84 | N/A |
| 12/31/2020 | 45 | -99 | -84 | -84 | N/A |
| 9/30/2020 | 29 | -109 | -83 | -82 | N/A |
| 6/30/2020 | 2 | -130 | -113 | -111 | N/A |
| 3/31/2020 | N/A | -130 | -108 | -105 | N/A |
| 12/31/2019 | N/A | -122 | -102 | -100 | N/A |
| 9/30/2019 | N/A | -111 | -93 | -91 | N/A |
| 6/30/2019 | N/A | -99 | -83 | -82 | N/A |
| 3/31/2019 | N/A | -89 | -79 | -78 | N/A |
| 12/31/2018 | N/A | -85 | -75 | -74 | N/A |
| 9/30/2018 | N/A | -78 | -68 | -68 | N/A |
| 6/30/2018 | N/A | -74 | -65 | -65 | N/A |
| 3/31/2018 | N/A | -68 | -60 | -59 | N/A |
| 12/31/2017 | N/A | -65 | N/A | -51 | N/A |
| 9/30/2017 | N/A | -60 | N/A | -45 | N/A |
| 6/30/2017 | N/A | -52 | N/A | -37 | N/A |
| 3/31/2017 | N/A | -45 | N/A | -29 | N/A |
| 12/31/2016 | N/A | -35 | N/A | -25 | N/A |
| 12/31/2015 | 1 | -22 | N/A | -14 | N/A |
| 12/31/2014 | 1 | -7 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GTHX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: GTHX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GTHX is expected to become profitable in the next 3 years.
Revenue vs Market: GTHX's revenue (21.3% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: GTHX's revenue (21.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GTHX's Return on Equity is forecast to be low in 3 years time (1.3%).